How to Invest in Psychedelics


Ryan Allway

February 3rd, 2020

Policy


Denver was one of the first cities in the country to legalize adult-use cannabis and its move to decriminalize psychedelics could open the door to an entirely new market. Like marijuana, advocates for magic mushrooms have had to overcome both stereotypes and excessive regulation to bring attention to its potentially significant medical benefits.

Some studies have found that psilocybin might help dramatically reduce the symptoms of depression and other mental health disorders, while others suggest that it could help with overcome nicotine and alcohol addictions. In fact, the effects from a single treatment session could last months or years, eliminating the need for pharmaceuticals.

State of Legalization

Psilocybin is a Schedule I Controlled Substance on a federal level, but it has been decriminalized in Denver, Colorado, Oakland, California and Santa Cruz, California. Oregon is also moving to decriminalize the substance on a state level, which could open the door to the first state-wide legal market, as well as more widespread therapeutic usage.

On a global level, psilocybin is a Schedule I drug under the United Nations 1971 Convention on Psychotropic Substances, although it has been shown to have numerous medicinal and religious uses, as well as significantly lower potential for abuse than other Schedule I drugs. The mushrooms are also unregulated by UN treaties.

Some countries have already legalized the mushrooms, including the Bahamas, Brazil, The Netherlands (as truffle), and Samoa. Other countries have no laws on the books or ambiguous laws that aren’t very clear about the legal status, including most of Asia (with the exception of Japan) and all of Africa. These dynamics could lead to a large international market.

Investing in Psychedelics

Psychedelics remain illegal on a federal level, but unlike cannabis, it also remains illegal on a state level. While there have been efforts to decriminalize psilocybin, these efforts are in the early states at the state level and have only gained ground in a handful of cities thus far. This makes the market very early-stage for investors.

There are also few public companies operating in the space given the early-stage nature of the market:

  • The Yield Growth Corp. (CSE: BOSS) is a Canadian wellness company that’s focused on cannabis and hemp products. Recently, the company acquired a portfolio of mushroom formulas and launched a new subsidiary, Flourish Mushroom Labs, which plans to expand into the psilocybin business.

Click here to receive an investor deck and learn more about BOSS

  • Roadman Investments Corp. (TSX-V: LITT) is a Canadian venture capital firm that recently invested in Champignon Brands, a British Columbia-based craft mushroom distributor with plans to expand into the psychedelic mushroom space.

 

  • Wuhan General Group (OTC: WUHN) is a Chinese alternative medicine company with interest in CBD and psilocybin, although both substances have an unclear legal standing in China, where the company is based.

Looking Ahead

Investors interested in investing in psychadelics have few options at the moment, but the growing legalization movement could prompt more companies to enter the space. Given the potential therapeutic value and existing international markets, investors may want to keep a close eye on the space over the coming months and years.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading